{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:57:30Z","timestamp":1786982250622,"version":"build-2736575974"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:00:00Z","timestamp":1683331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:00:00Z","timestamp":1683331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Advanced breast cancer represents a challenge for patients and for physicians due its dynamic genomic changes yielding to a resistance to treatments. The main goal is to improve quality of live and survival of the patients through the most appropriate subsequent therapies based on the knowledge of the natural history of the disease. In these guidelines, we summarize current evidence and available therapies for the medical management of advanced breast cancer.<\/jats:p>","DOI":"10.1007\/s12094-023-03203-8","type":"journal-article","created":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T06:01:47Z","timestamp":1683352907000},"page":"2665-2678","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["SEOM\u2013GEICAM\u2013SOLTI clinical guidelines in advanced breast cancer (2022)"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6880-0301","authenticated-orcid":false,"given":"Jose Angel","family":"Garcia-Saenz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5867-6615","authenticated-orcid":false,"given":"Isabel","family":"Blancas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1156-7681","authenticated-orcid":false,"given":"Isabel","family":"Echavarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5443-7847","authenticated-orcid":false,"given":"Carmen","family":"Hinojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Margeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8933-0687","authenticated-orcid":false,"given":"Fernando","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1485-5080","authenticated-orcid":false,"given":"Sonia","family":"Pernas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3490-3585","authenticated-orcid":false,"given":"Teresa","family":"Ramon y Cajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3194-7398","authenticated-orcid":false,"given":"Nuria","family":"Ribelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meritxell","family":"Bellet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,6]]},"reference":[{"key":"3203_CR1","unstructured":"SEOM: Las Cifras Del C\u00e1ncer En Espa\u00f1a. 2022. available at: https:\/\/seom.org\/images\/LAS_CIFRAS_DEL_CANCER_EN_ESPANA_2022.pdf"},{"key":"3203_CR2","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","volume":"31","author":"F Mosele","year":"2020","unstructured":"Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision medicine Working Group. Ann Oncol. 2020;31:1491\u2013505.","journal-title":"Ann Oncol"},{"key":"3203_CR3","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380:1929\u201340.","journal-title":"N Engl J Med"},{"key":"3203_CR4","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32:1475\u201395.","journal-title":"Ann Oncol"},{"key":"3203_CR5","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1053\/j.semnuclmed.2022.03.004","volume":"52","author":"MG Hildebrandt","year":"2022","unstructured":"Hildebrandt MG, Naghavi-Behzad M, Vogsen M. A role of FDG-PET\/CT for response evaluation in metastatic breast cancer? Semin Nucl Med. 2022;52:520\u201330.","journal-title":"Semin Nucl Med"},{"key":"3203_CR6","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andr\u00e9 F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31:1623\u201349.","journal-title":"Ann Oncol"},{"key":"3203_CR7","unstructured":"National Comprehensive Cancer Networ. NCCN Guidelines Version 4.2022 Invasive Breast Cancer."},{"key":"3203_CR8","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1001\/jamaoncol.2021.4301","volume":"7","author":"A Llombart-Cussac","year":"2021","unstructured":"Llombart-Cussac A, P\u00e9rez-Garc\u00eda JM, Bellet M, Dalenc F, Gil-Gil M, Ru\u00edz-Borrego M, et al. Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021;7:1791\u20139.","journal-title":"JAMA Oncol"},{"key":"3203_CR9","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol. 2018;36:2465\u201372.","journal-title":"J Clin Oncol"},{"key":"3203_CR10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(21)00034-6","volume":"22","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2021;22:489\u201398.","journal-title":"Lancet Oncol"},{"key":"3203_CR11","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1200\/JCO.21.01392","volume":"39","author":"HJ Burstein","year":"2021","unstructured":"Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, et al. Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2\u2013Negative Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2021;39:3959\u201377.","journal-title":"J Clin Oncol"},{"key":"3203_CR12","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"36","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;36:520\u20139.","journal-title":"N Engl J Med"},{"key":"3203_CR13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s12094-021-02708-4","volume":"24","author":"P Garc\u00eda-Alfonso","year":"2022","unstructured":"Garc\u00eda-Alfonso P, Saiz-Rodr\u00edguez M, Mond\u00e9jar R, Salazar J, P\u00e1ez D, Borobia AM, et al. Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines. Clin Transl Oncol. 2022;24:483\u201394.","journal-title":"Clin Transl Oncol"},{"key":"3203_CR14","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O\u2019Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377:914\u201323.","journal-title":"Lancet"},{"key":"3203_CR15","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/jnci\/djz211","volume":"112","author":"SP Hey","year":"2020","unstructured":"Hey SP, Gyawali B, D\u2019Andrea E, Kanagaraj M, Franklin JM, Kesselheim AS. A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises. J Natl Cancer Inst. 2020;112:335\u201342.","journal-title":"J Natl Cancer Inst"},{"key":"3203_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387:9\u201320.","journal-title":"N Engl J Med"},{"key":"3203_CR17","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1200\/JCO.22.01002","volume":"40","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F, Cortes J, Schmid P, Loirat D, et al. Sacituzumab Govitecan in Hormone Receptor-Positive\/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin Oncol. 2022;40:3365\u201376.","journal-title":"J Clin Oncol"},{"key":"3203_CR18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377:523\u201333.","journal-title":"N Engl J Med"},{"key":"3203_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19:91\u2013113.","journal-title":"Nat Rev Clin Oncol"},{"key":"3203_CR20","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1200\/JCO.22.01063","volume":"40","author":"NL Henry","year":"2022","unstructured":"Henry NL, Somerfield MR, Dayao Z, Elias A, Kalinsky K, McShane LM, et al. Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2022;40:3205\u201321.","journal-title":"J Clin Oncol"},{"key":"3203_CR21","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379:2108\u201321.","journal-title":"N Engl J Med"},{"key":"3203_CR22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","volume":"21","author":"P Schmid","year":"2020","unstructured":"Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:44\u201359.","journal-title":"Lancet Oncol"},{"key":"3203_CR23","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","volume":"32","author":"D Miles","year":"2021","unstructured":"Miles D, Gligorov J, Andr\u00e9 F, Cameron D, Schneeweiss A, Barrios C, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer. Ann Oncol. 2021;32:994\u20131004.","journal-title":"Ann Oncol"},{"key":"3203_CR24","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817\u201328.","journal-title":"Lancet"},{"key":"3203_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2022;387:217\u201326.","journal-title":"N Engl J Med"},{"key":"3203_CR26","doi-asserted-by":"crossref","unstructured":"Dear RF, McGeechan K, Jenkins MC, Barratt A, Tattersall MH, Wilcken N. Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2013;:CD008792","DOI":"10.1002\/14651858.CD008792.pub2"},{"key":"3203_CR27","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1200\/JCO.2010.31.5374","volume":"29","author":"A Gennari","year":"2011","unstructured":"Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol. 2011;29:2144\u20139.","journal-title":"J Clin Oncol"},{"key":"3203_CR28","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","volume":"24","author":"A Gennari","year":"2018","unstructured":"Gennari A, Stockler M, Puntoni M, Sormani M, Nanni O, Amadori D, et al. Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018;24:628\u201337.","journal-title":"Nat Med"},{"key":"3203_CR29","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1093\/annonc\/mdt276","volume":"24","author":"DW Miles","year":"2013","unstructured":"Miles DW, Di\u00e9ras V, Cort\u00e9s J, Duenne AA, Yi J, O\u2019Shaughnessy J. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol. 2013;24:2773\u201380.","journal-title":"Ann Oncol"},{"key":"3203_CR30","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S1470-2045(14)70444-9","volume":"15","author":"J Gligorov","year":"2014","unstructured":"Gligorov J, Doval D, Bines J, Alba E, Cortes P, Pierga JY, et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1351\u201360.","journal-title":"Lancet Oncol"},{"key":"3203_CR31","doi-asserted-by":"crossref","unstructured":"Egger SJ, Willson ML, Morgan J, Walker HS, Carrick S, Ghersi D, et\u00a0al. Platinum-containing regimens for metastatic breast cancer. Cochrane Database 2017;6:CD003374","DOI":"10.1002\/14651858.CD003374.pub4"},{"key":"3203_CR32","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ejca.2003.11.007","volume":"40","author":"P Fumoleau","year":"2004","unstructured":"Fumoleau P, Largillier R, Clippe C, Di\u00e8ras V, Orfeuvre H, Lesimple T, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer. 2004;40:536\u201342.","journal-title":"Eur J Cancer"},{"key":"3203_CR33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10549-004-2468-4","volume":"90","author":"SY Rha","year":"2005","unstructured":"Rha SY, Moon YH, Jeung HC, Kim YT, Sohn JH, Yang WI, et al. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat. 2005;90:215\u201321.","journal-title":"Breast Cancer Res Treat"},{"key":"3203_CR34","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1023\/A:1008364222793","volume":"10","author":"C Vogel","year":"1999","unstructured":"Vogel C, O\u2019Rourke M, Winer E, Hochster H, Chang A, Adamkiewicz B, et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol. 1999;10:397\u2013402.","journal-title":"Ann Oncol"},{"key":"3203_CR35","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021;384:1529\u201341.","journal-title":"N Engl J Med"},{"key":"3203_CR36","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/ college of American pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36:2105\u201322.","journal-title":"J Clin Oncol"},{"key":"3203_CR37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cort\u00e9s J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109\u201319.","journal-title":"N Engl J Med"},{"key":"3203_CR38","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13058-016-0773-6","volume":"18","author":"EA Perez","year":"2016","unstructured":"Perez EA, L\u00f3pez-Vega JM, Petit T, Zamagni C, Easton V, Kamber J, et al. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results. Breast Cancer Res. 2016;18:126.","journal-title":"Breast Cancer Res"},{"key":"3203_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.breast.2011.07.006","volume":"21","author":"J Huober","year":"2012","unstructured":"Huober J, Fasching PA, Barsoum M, Petruzelka L, Wallwiener D, Thomssen C, et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer\u2014results of the eLEcTRA trial. Breast. 2012;21:27\u201333.","journal-title":"Breast"},{"key":"3203_CR40","doi-asserted-by":"publisher","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","volume":"27","author":"S Johnston","year":"2009","unstructured":"Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009;27:5538\u201346.","journal-title":"J Clin Oncol"},{"key":"3203_CR41","doi-asserted-by":"publisher","first-page":"5529","DOI":"10.1200\/JCO.2008.20.6847","volume":"27","author":"B Kaufman","year":"2009","unstructured":"Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009;27:5529\u201337.","journal-title":"J Clin Oncol"},{"key":"3203_CR42","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783\u201391.","journal-title":"N Engl J Med"},{"key":"3203_CR43","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022;386:1143\u201354.","journal-title":"N Engl J Med"},{"key":"3203_CR44","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SAA, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020;382:597\u2013609.","journal-title":"N Engl J Med"},{"key":"3203_CR45","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","volume":"28","author":"KL Blackwell","year":"2010","unstructured":"Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28:1124\u201330.","journal-title":"J Clin Oncol"},{"key":"3203_CR46","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa2005936","volume":"384","author":"C Hu","year":"2021","unstructured":"Hu C, Hart SN, Gnanaolivu R, Huang H, Lee KY, Na J, et al. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med. 2021;384:440\u201351.","journal-title":"N Engl J Med"},{"key":"3203_CR47","doi-asserted-by":"crossref","unstructured":"Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gon\u00e7alves A, Lee KH, al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018; 379:753\u2013763.","DOI":"10.1056\/NEJMoa1802905"},{"issue":"6","key":"3203_CR48","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/neuonc\/noaa285","volume":"23","author":"M Kuksis","year":"2021","unstructured":"Kuksis M, Gao Y, Tran W, Hoey C, Kiss A, Komorowski AS, et al. The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. Neuro Oncol. 2021;23(6):894\u2013904.","journal-title":"Neuro Oncol"},{"issue":"2","key":"3203_CR49","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ijrobp.2020.01.051","volume":"107","author":"PW Sperduto","year":"2020","unstructured":"Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, et al. Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today. Int J Radiat Oncol Biol Phys. 2020;107(2):334\u201343.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"3203_CR50","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1016\/j.clbc.2019.06.007","volume":"20","author":"AS Komorowski","year":"2020","unstructured":"Komorowski AS, Warner E, MacKay HJ, et al. Incidence of brain metastases in non-metastatic and metastatic breast cancer: is there a role for screening? Clin Breast Cancer. 2020;20(1):e54\u201364.","journal-title":"Clin Breast Cancer"},{"issue":"11","key":"3203_CR51","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","volume":"32","author":"AS Komorowski","year":"2021","unstructured":"Komorowski AS, Warner E, MacKay HJ, Sahgal A, Pritchard KI, Jerzak KJ. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann Oncol. 2021;32(11):1332\u201347.","journal-title":"Ann Oncol"},{"issue":"23","key":"3203_CR52","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.22.00520","volume":"40","author":"N Ramakrishna","year":"2022","unstructured":"Ramakrishna N, Anders CK, Lin NU, Morikawa A, Temin S, Chandarlapaty S, et al. Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update. J Clin Oncol. 2022;40(23):2636\u201355.","journal-title":"J Clin Oncol"},{"key":"3203_CR53","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10549-020-05552-2","volume":"180","author":"MN Mills","year":"2020","unstructured":"Mills MN, Figura NB, Arrington JA, Yu HM, Etame AB, Vogelbaum MA, et al. Management of brain metastases in breast cancer: a review of current practices and emerging treatments. Breast Cancer Res Treat. 2020;180:279\u2013300.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"3203_CR54","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13058-020-01372-w","volume":"22","author":"JP Leone","year":"2020","unstructured":"Leone JP, Emblem KE, Weitz M, Gelman RS, Schneider BP, Freedman RA, et al. Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases. Breast Cancer Res. 2020;22(1):131.","journal-title":"Breast Cancer Res"},{"key":"3203_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102114","volume":"91","author":"A van Ommen-Nijhof","year":"2020","unstructured":"van Ommen-Nijhof A, Steenbruggen TG, Schats W, Wiersma T, Horlings HM, Mann R, et al. Prognostic factors in patients with oligometastatic breast cancer - A systematic review. Cancer Treat Rev. 2020;91: 102114.","journal-title":"Cancer Treat Rev"},{"key":"3203_CR56","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.radonc.2021.09.031","volume":"164","author":"GA Viani","year":"2021","unstructured":"Viani GA, Gouveia AG, Louie AV, Korzeniowski M, Pavoni JF, Hamamura AC, et al. Stereotactic body radiotherapy to treat breast cancer oligometastases: A systematic review with meta-analysis. Radiother Oncol. 2021;164:245\u201350.","journal-title":"Radiother Oncol"},{"key":"3203_CR57","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s10549-010-1195-2","volume":"126","author":"YC Ding","year":"2011","unstructured":"Ding YC, Steele L, Kuan C-J, Greilac S, Neuhausen SL. Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res Treat. 2011;126:771\u20138.","journal-title":"Breast Cancer Res Treat"},{"key":"3203_CR58","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/cpt.2454","volume":"111","author":"AL Kraus","year":"2022","unstructured":"Kraus AL, Yu-Kite M, Mardekian J, Cotter MJ, Kim S, Decembrino J, et al. Real-World Data of Palbociclib in Combination With Endocrine Therapy for the Treatment of Metastatic Breast Cancer in Men. Clin Pharmacol Ther. 2022;111:302\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"3203_CR59","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1200\/JCO.19.03120","volume":"38","author":"MJ Hassett","year":"2020","unstructured":"Hassett MJ, Somerfield MR, Baker ER, Cardoso F, Kansal KJ, Kwait DC, et al. Management of male breast cancer: ASCO guideline. J Clin Oncol. 2020;38:1849\u201363.","journal-title":"J Clin Oncol"},{"key":"3203_CR60","doi-asserted-by":"crossref","unstructured":"Caswell-Jin JL, Plevritis SK, Tian L, Cadham CJ, Xu C, Stout NK, et al. Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review. JNCI Cancer Spectr. 2018;2:pky062","DOI":"10.1093\/jncics\/pky062"}],"updated-by":[{"DOI":"10.1007\/s12094-023-03229-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000}}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03203-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-023-03203-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03203-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T08:14:41Z","timestamp":1692000881000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-023-03203-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,6]]},"references-count":60,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["3203"],"URL":"https:\/\/doi.org\/10.1007\/s12094-023-03203-8","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,6]]},"assertion":[{"value":"14 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12094-023-03229-y","URL":"https:\/\/doi.org\/10.1007\/s12094-023-03229-y","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JAG-S reports Advisory Board and Speaker from\u00a0Novartis, Lilly, Daiichi Sankyo, Gilead; Advisory Board from\u00a0AstraZeneca, Pierre Fabre, EISAI; Grant from\u00a0Seagen; Speaker from\u00a0Roche, Asofarma and Exact Sciences and Advisory Board and Grant from\u00a0Stemline Menarini. IBL-B reports Advisory Board, Speaker and Grant from Roche, Lilly and Astrazeneca; Advisory Board and Speaker from Novartis, Celgene, Eisai, Pierre Fabre, BMS, Daiichi Sankyo, Gr\u00fcnenthal, Seagen and Veracyte and Grant from Agendia. IE reports Advisory Board and Speaker from Lilly, Speaker from Pfizer, Novartis; Advisory Board from AstraZeneca; Speaker from Roche and Pierre Fabre. MMV reports Advisory Board from Gilead, Lilly Piere Fabre Daichy Eisai; Grant from Pfizer and Speaker from Pierre Fabre. FMA reports Advisory Board, Speaker, Grant and others from\u00a0Pfizer; Advisory Board from\u00a0Novartis, Daiichi Sankyo, Astra Zeneca; Others from\u00a0MSD, Pierre Fabre, Gilead, Seagen and\u00a0Roche. SP reports Advisory Board, Speaker and Non-financial Support from AstraZeneca and Daiichi; Advisory Board and Grant from Roche; Speaker and Non-financial Support from Lilly and Novartis; Advisory Board from Pierre Fabre and Seagen; Non-financial Support from Gilead; Advisory Board and Non-financial Support from Pfizer and Speaker from Eisai. MBE reports Speaker from Pfizer, Lilly, Novartis; Advisory Board from Pfizer, Lilly, Novartis and Stemline Menarini and Travel Expenses from Pfizer. CH, TRC, and NR have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"As this manuscript is not a clinical trial but a review article, no ethical approval and informed consent is needed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and Informed consent"}}]}}